BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li N, Gao W, Zhang YF, Ho M. Glypicans as Cancer Therapeutic Targets. Trends Cancer 2018;4:741-54. [PMID: 30352677 DOI: 10.1016/j.trecan.2018.09.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Shen J, Cai W, Ma Y, Xu R, Huo Z, Song L, Qiu X, Zhang Y, Li A, Cao W, Zhou S, Tang X. hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway.Nanoscale Res Lett. 2020;15:220. [PMID: 33242103 DOI: 10.1186/s11671-020-03451-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Allen NJ. Brain tumours manipulate neighbouring synapses. Nature 2020;578:46-7. [DOI: 10.1038/d41586-020-00137-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Pan J, Ho M. Role of glypican-1 in regulating multiple cellular signaling pathways. Am J Physiol Cell Physiol 2021;321:C846-58. [PMID: 34550795 DOI: 10.1152/ajpcell.00290.2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang S, Qiu Y, Bai B. The Expression, Regulation, and Biomarker Potential of Glypican-1 in Cancer. Front Oncol 2019;9:614. [PMID: 31355137 DOI: 10.3389/fonc.2019.00614] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
5 Wang JY, Wang XK, Zhu GZ, Zhou X, Yao J, Ma XP, Wang B, Peng T. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer 2021;21:462. [PMID: 33902495 DOI: 10.1186/s12885-021-08104-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wiedemeyer K, Köbel M, Koelkebeck H, Xiao Z, Vashisht K. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. Hum Pathol 2020;98:56-63. [PMID: 32017945 DOI: 10.1016/j.humpath.2020.01.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T, Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer 2021;9:e001875. [PMID: 33833049 DOI: 10.1136/jitc-2020-001875] [Reference Citation Analysis]
8 Barkovskaya A, Buffone A Jr, Žídek M, Weaver VM. Proteoglycans as Mediators of Cancer Tissue Mechanics. Front Cell Dev Biol 2020;8:569377. [PMID: 33330449 DOI: 10.3389/fcell.2020.569377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang M, Wang D, Su L, Ma J, Wang S, Cui M, Hong S, Guan B, Ma X. Activity of Wnt/PCP Regulation Pathway Classifies Patients of Low-Grade Glioma Into Molecularly Distinct Subgroups With Prognostic Difference. Front Oncol 2021;11:726034. [PMID: 34540693 DOI: 10.3389/fonc.2021.726034] [Reference Citation Analysis]
10 Furman WL. Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics 2021;15:205-19. [PMID: 34135571 DOI: 10.2147/BTT.S267278] [Reference Citation Analysis]
11 Gopal S, Arokiasamy S, Pataki C, Whiteford JR, Couchman JR. Syndecan receptors: pericellular regulators in development and inflammatory disease. Open Biol 2021;11:200377. [PMID: 33561383 DOI: 10.1098/rsob.200377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Hu C, Jiang W, Lv M, Fan S, Lu Y, Wu Q, Pi J. Potentiality of Exosomal Proteins as Novel Cancer Biomarkers for Liquid Biopsy. Front Immunol 2022;13:792046. [PMID: 35757760 DOI: 10.3389/fimmu.2022.792046] [Reference Citation Analysis]
13 Takeuchi M, Takeuchi K, Takai T, Yamaguchi R, Furukawa T, Akagi KI, Takeuchi JK. Subcellular localization of glypican-5 is associated with dynamic motility of the human mesenchymal stem cell line U3DT. PLoS One 2021;16:e0226538. [PMID: 33606708 DOI: 10.1371/journal.pone.0226538] [Reference Citation Analysis]
14 Murali M, Kumar AR, Nair B, Pavithran K, Devan AR, Pradeep GK, Nath LR. Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clin Transl Oncol 2021. [PMID: 34595736 DOI: 10.1007/s12094-021-02707-5] [Reference Citation Analysis]
15 Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer. 2020;11:2008-2021. [PMID: 32127929 DOI: 10.7150/jca.39972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
16 Grillo PK, Győrffy B, Götte M. Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients. J Cancer Res Clin Oncol 2021;147:1937-55. [PMID: 33742285 DOI: 10.1007/s00432-021-03597-4] [Reference Citation Analysis]
17 Espinoza-Sánchez NA, Götte M. Role of cell surface proteoglycans in cancer immunotherapy. Semin Cancer Biol 2020;62:48-67. [PMID: 31336150 DOI: 10.1016/j.semcancer.2019.07.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
18 Lanzi C, Cassinelli G. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities. Biochemical Pharmacology 2020;178:114084. [DOI: 10.1016/j.bcp.2020.114084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Ghosh S, Huda P, Fletcher N, Campbell D, Thurecht KJ, Walsh B. Clinical development of an anti-GPC-1 antibody for the treatment of cancer. Expert Opinion on Biological Therapy. [DOI: 10.1080/14712598.2022.2033204] [Reference Citation Analysis]
20 Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology 2022;11:2010894. [DOI: 10.1080/2162402x.2021.2010894] [Reference Citation Analysis]
21 Zhao S, Wu C, Gao Z, Li X, Guo Z, Wang Z. Notch signaling governs the expression of glypican Dally to define the stem cell niche. Biol Open 2020;9:bio047696. [PMID: 31826854 DOI: 10.1242/bio.047696] [Reference Citation Analysis]
22 Buffone A, Weaver VM. Don't sugarcoat it: How glycocalyx composition influences cancer progression. J Cell Biol 2020;219:e201910070. [PMID: 31874115 DOI: 10.1083/jcb.201910070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
23 Palmisani F, Kovar H, Kager L, Amann G, Metzelder M, Bergmann M. Systematic review of the immunological landscape of Wilms tumors. Mol Ther Oncolytics 2021;22:454-67. [PMID: 34553032 DOI: 10.1016/j.omto.2021.06.016] [Reference Citation Analysis]
24 Kaur SP, Cummings BS. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol 2019;168:108-18. [PMID: 31251939 DOI: 10.1016/j.bcp.2019.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
25 Annaval T, Wild R, Crétinon Y, Sadir R, Vivès RR, Lortat-Jacob H. Heparan Sulfate Proteoglycans Biosynthesis and Post Synthesis Mechanisms Combine Few Enzymes and Few Core Proteins to Generate Extensive Structural and Functional Diversity. Molecules 2020;25:E4215. [PMID: 32937952 DOI: 10.3390/molecules25184215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Bartolini B, Caravà E, Caon I, Parnigoni A, Moretto P, Passi A, Vigetti D, Viola M, Karousou E. Heparan Sulfate in the Tumor Microenvironment. Adv Exp Med Biol 2020;1245:147-61. [PMID: 32266657 DOI: 10.1007/978-3-030-40146-7_7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Front Immunol 2022;13:857308. [PMID: 35345673 DOI: 10.3389/fimmu.2022.857308] [Reference Citation Analysis]
28 Pezeshki PS, Moeinafshar A, Ghaemdoust F, Razi S, Keshavarz-Fathi M, Rezaei N. Advances in pharmacotherapy for neuroblastoma. Expert Opin Pharmacother 2021;:1-22. [PMID: 34254549 DOI: 10.1080/14656566.2021.1953470] [Reference Citation Analysis]
29 Fleming BD, Ho M. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules 2020;10:E934. [PMID: 32575752 DOI: 10.3390/biom10060934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, Liang X, Feng M, Yang X, Ho M. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Sci Rep 2021;11:40. [PMID: 33420124 DOI: 10.1038/s41598-020-79524-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Shin WR, Park DY, Kim JH, Lee JP, Thai NQ, Oh IH, Sekhon SS, Choi W, Kim SY, Cho BK, Kim SC, Min J, Ahn JY, Kim YH. Structure based innovative approach to analyze aptaprobe-GPC3 complexes in hepatocellular carcinoma. J Nanobiotechnology 2022;20:204. [PMID: 35477501 DOI: 10.1186/s12951-022-01391-z] [Reference Citation Analysis]
32 Kamakura D, Asano R, Yasunaga M. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals (Basel) 2021;14:1172. [PMID: 34832954 DOI: 10.3390/ph14111172] [Reference Citation Analysis]
33 Schlaepfer Sales CB, Guimarães VSN, Valverde LF, Dias RB, Freitas RD, Siquara da Rocha LO, Coelho de Miranda M, Vilas Bôas DS, Gonçalves Agra IM, Dos Santos JN, Gurgel Rocha CA. Glypican-1, -3, -5 (GPC1, GPC3, GPC5) and Hedgehog Pathway Expression in Oral Squamous Cell Carcinoma. Appl Immunohistochem Mol Morphol 2021;29:345-51. [PMID: 33512817 DOI: 10.1097/PAI.0000000000000907] [Reference Citation Analysis]
34 Zhang H, Deng M, Pei F, Wang S, Ho M. Next-Generation Antibody Therapeutics: Discovery, Development and Beyond: highlights of the third annual conference of the Chinese Antibody Society. Antib Ther 2019;2:99-107. [PMID: 31942535 DOI: 10.1093/abt/tbz012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther 2020;3:109-14. [PMID: 32566896 DOI: 10.1093/abt/tbaa009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
36 Kolluri A, Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer. Front Oncol 2019;9:708. [PMID: 31428581 DOI: 10.3389/fonc.2019.00708] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
37 Lin L, He Y, Ni Z, Zhang M, Liu J, Mao Q, Huang B, Lin J. GPC2 deficiency inhibits cell growth and metastasis in colon adenocarcinoma. Open Medicine 2022;17:304-16. [DOI: 10.1515/med-2022-0421] [Reference Citation Analysis]
38 Zhao X, Ren Y, Lu Z. Potential diagnostic and therapeutic roles of exosomes in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2020;1874:188414. [PMID: 32866530 DOI: 10.1016/j.bbcan.2020.188414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 2021;:100791. [PMID: 34538649 DOI: 10.1016/j.currproblcancer.2021.100791] [Reference Citation Analysis]
40 Della Rosa G, Ruggeri C, Aloisi A. From Exosome Glycobiology to Exosome Glycotechnology, the Role of Natural Occurring Polysaccharides. Polysaccharides 2021;2:311-38. [DOI: 10.3390/polysaccharides2020021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Li N, Spetz MR, Ho M. The Role of Glypicans in Cancer Progression and Therapy. J Histochem Cytochem 2020;68:841-62. [PMID: 32623934 DOI: 10.1369/0022155420933709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
42 Li N, Torres MB, Spetz MR, Wang R, Peng L, Tian M, Dower CM, Nguyen R, Sun M, Tai CH, de Val N, Cachau R, Wu X, Hewitt SM, Kaplan RN, Khan J, St Croix B, Thiele CJ, Ho M. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice. Cell Rep Med 2021;2:100297. [PMID: 34195677 DOI: 10.1016/j.xcrm.2021.100297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ma Y, Liu Y, Teng L, Luo E, Liu D, Zhou F, Wang K, Chen W, Bi L. Zi Shen Decoction Inhibits Growth and Metastasis of Lung Cancer via Regulating the AKT/GSK-3β/β-Catenin Pathway. Oxid Med Cell Longev 2021;2021:6685282. [PMID: 33777320 DOI: 10.1155/2021/6685282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Nomura K, Kitanaka A, Iwama H, Tani J, Nomura T, Nakahara M, Ohura K, Tadokoro T, Fujita K, Mimura S, Yoneyama H, Kobara H, Morishita A, Okano K, Suzuki Y, Tsutsi K, Himoto T, Masaki T. Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. Oncol Lett 2021;21:229. [PMID: 33613718 DOI: 10.3892/ol.2021.12490] [Reference Citation Analysis]
45 Liu X, Gao F, Jiang L, Jia M, Ao L, Lu M, Gou L, Ho M, Jia S, Chen F, Gao W. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. J Transl Med 2020;18:295. [PMID: 32746924 DOI: 10.1186/s12967-020-02462-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Liu JQ, Liao XW, Wang XK, Yang CK, Zhou X, Liu ZQ, Han QF, Fu TH, Zhu GZ, Han CY, Su H, Huang JL, Ruan GT, Yan L, Ye XP, Peng T. Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms.BMC Gastroenterol. 2020;20:415. [PMID: 33302876 DOI: 10.1186/s12876-020-01560-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Xia Y, Li Y, Fu BM. Differential effects of vascular endothelial growth factor on glycocalyx of endothelial and tumor cells and potential targets for tumor metastasis. APL Bioengineering 2022;6:016101. [DOI: 10.1063/5.0064381] [Reference Citation Analysis]
48 De Pasquale V, Pavone LM. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment. Int J Mol Sci 2020;21:E6588. [PMID: 32916872 DOI: 10.3390/ijms21186588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
49 Hassan N, Greve B, Espinoza-Sánchez NA, Götte M. Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer. Cell Signal 2021;77:109822. [PMID: 33152440 DOI: 10.1016/j.cellsig.2020.109822] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
50 Contreras M, Villar M, de la Fuente J. A Vaccinomics Approach for the Identification of Tick Protective Antigens for the Control of Ixodes ricinus and Dermacentor reticulatus Infestations in Companion Animals. Front Physiol 2019;10:977. [PMID: 31417430 DOI: 10.3389/fphys.2019.00977] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
51 Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. [PMID: 34922633 DOI: 10.1186/s40164-021-00250-1] [Reference Citation Analysis]
52 Faria-Ramos I, Poças J, Marques C, Santos-Antunes J, Macedo G, Reis CA, Magalhães A. Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management. Biomolecules 2021;11:136. [PMID: 33494442 DOI: 10.3390/biom11020136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]